BPG is committed to discovery and dissemination of knowledge
Articles in Press
2/7/2024 6:37:34 AM | Browse: 78 | Download: 0
Publication Name World Journal of Gastrointestinal Oncology
Manuscript ID 90598
Country/Territory China
Category Oncology
Manuscript Type Clinical and Translational Research
Article Title NOX4 promotes tumor progression through the MAPK-MEK1/2-ERK1/2 axis in colorectal cancer
Manuscript Source Unsolicited Manuscript
All Author List Yu-Jie Xu, Ya-Chang Huo, Qi-Tai Zhao, Jin-Yan Liu, Yi-Jun Tian, Lei-Lei Yang and Yi Zhang
Funding Agency and Grant Number
Funding Agency Grant Number
Henan Province Medical Science and Technology Research Provincial and Ministry Co-constructed Projects SBGJ202101010
Major Public Welfare Projects in Henan Province 201300310400
Joint Construction Project of Henan Medical Science and Technology Research Plan LHGJ20220050
Major Science and Technology Project of Henan Province 221100310100
Corresponding Author Yi Zhang, MD, PhD, Chief Physician, Full Professor, Biotherapy Center and Cancer Center, The First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe East Road, Zhengzhou 450052, Henan Province, China. yizhang@zzu.edu.cn
Key Words Colorectal cancer; Metabolic reprogramming; Metastasis; Nicotinamide adenine dinucleotide phosphate oxidase 4; Mitogen-activated protein kinase signaling
Core Tip We first identified three clusters with different survival status based on dysregulated metabolic genes in colorectal cancer (CRC). In addition, based on differentially expressed survival-related metabolic genes, we constructed and validated a prediction model using different cohorts. Among these genes, nicotinamide adenine dinucleotide phosphate oxidase 4 (NOX4) overexpression activated the mitogen-activated protein kinase-MEK1/2-ERK1/2 signaling pathway to promote cancer metastasis, whereas trametinib (a MEK1/2 inhibitor) treatment reversed this effect. Our study analyzed metabolic gene expression and highlighted the importance of NOX4 in promoting CRC metastasis, suggesting that NOX4 could be a new therapeutic target and modulating the response to clinical therapy.
Citation Xu YJ, Huo YC, Zhao QT, Liu JY, Tian YJ, Yang LL, Zhang Y. NOX4 promotes tumor progression through the MAPK-MEK1/2-ERK1/2 axis in colorectal cancer. World J Gastrointest Oncol 2024; In press
Received
2023-12-08 13:30
Peer-Review Started
2023-12-08 13:30
To Make the First Decision
Return for Revision
2023-12-22 11:45
Revised
2024-01-04 13:56
Second Decision
2024-02-07 02:45
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2024-02-07 06:37
Articles in Press
2024-02-07 06:37
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
ISSN 1948-5204 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com